Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 15/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457876 | 0.92 | IGF1R (0.61) | IGF1RAURKAAURKB | |
| SCHEMBL11340316 | 0.90 | IGF1R (0.79) | IGF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL4458462 | 0.85 | IGF1R (0.75) | IGF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL12439772 | 0.82 | IGF1R (0.67) | IGF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL4470599 | 0.82 | IGF1R (0.72) | IGF1RCDK19ALK | |
| SCHEMBL11341564 | 0.81 | IGF1R (0.78) | IGF1RAURKAAURKB | |
| SCHEMBL14320030 | 0.81 | IGF1R (0.67) | IGF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL11342893 | 0.81 | IGF1R (0.75) | IGF1RNTRK1NTRK3NTRK2CDK19 | |
| SCHEMBL4464176 | 0.80 | IGF1R (0.75) | IGF1RAURKAAURKB | |
| SCHEMBL12438499 | 0.80 | IGF1R (0.61) | IGF1RNTRK1CDK19ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-1841760-B1 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |